Accelerating ADC Innovation …because patients are waiting February 2022 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning Mersana Therapeutics, Inc.'s (the "Company's") business strategy and the design, p ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2021 Earnings Conference Call February 28, 2022 8:00 AM ET Company Participants James Salierno - Associate Director, Investor Relations. Anna Protopapas - President & CEO Arvin Yang - Senior Vice President & Chief Medical Officer Brian DeSchuytner - Senior Vice President &Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Leerink Boris Peaker - Cowen Colleen Kusy - Baird Capital Kaveri Pohlman - BTIG Jessica Fye - JPMorgan Operator Good morn ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2021 Earnings Conference Call November 9, 2021 8:00 AM ET Company Participants Sarah Carmody - Executive Director, IR & Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - SVP & Chief Medical Officer Timothy Lowinger - Chief Science & Technology Officer Brian DeSchuytner - SVP & CFO Conference Call Participants Boris Peaker - Cowen and Company Kaveri Pohlman - BTIG Daniel Wolle - JPMorgan Chase & Co. Colleen Kusy - Robert W. Baird & C ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Sarah Carmody - Executive Director, IR & Corporate Communications Anna Protopapas - President, CEO & Director Brian DeSchuytner - SVP, Finance & Product Strategy Timothy Lowinger - Chief Science & Technology Officer Arvin Yang - SVP & Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Kaveri Pohlman - BTIG Boris Peaker - Cowen and Company Jessica Fye - JPMorga ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President and CEO Arvin Yang - Chief Medical Officer Tim Lowinger - Chief Science and Technology Officer Brian DeSchuytner - Senior Vice President, Finance and Product Strategy Alejandra Carvajal - Chief Legal Officer Conference Call Participants Jonathan Chang - SVB Leerink Daniel McElligo ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2020 Earnings Conference Call February 26, 2021 8:00 AM ET Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President and Chief Executive Officer Arvin Yang - Senior Vice President and Chief Medical Officer Timothy Lowinger - Chief Science and Technology Officer Brian DeSchuytner - Senior Vice President of Finance and Product Strategy Carla Poulson - Chief Human Resources Officer Conference ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Sarah Carmody ??? Executive Director, Investor Relations and Corporate Communications Anna Protopapas ??? President and Chief Executive Officer Brian DeSchuytner ??? Senior Vice President-Finance and Product Strategy Tim Lowinger ??? Chief Science and Technology Officer Chuck Miller ??? Senior Vice President-Regulatory Affairs Conference Call Participants Jonathan Chang ??? SVB Leerink ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2020 Earnings Conference Call August 7, 2020 8:00 AM ET Company Participants Sarah Carmody ??? Executive Director, Investor Relations and Corporate Communications Anna Protopapas ??? President and Chief Executive Officer Tim Lowinger ??? Chief Science and Technology Officer Brian DeSchuytner ??? Senior Vice President Finance and Product Strategy Conference Call Participants Jonathan Chang ??? SVB Leerink Boris Peaker ??? Cowen Tom Shrader ??? BTIG Mike Ulz ??? Bai ...

XMT-1536 Interim Expansion Data from Phase 1 Study May 27, 2020 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company's business strategy and the design, progression and timing of its clinical tri ...

3549: Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC) Debra L. Richardson, Minal A. Barve, James F. Strauss, Susanna V. Ulahannan, Kathleen N. Moore, Erika P. Hamilton, Melissa L. Johnson, Kyriakos P. Papadopoulos, Corrine Zarwan, Charles K. Anderson, Joseph Buscema, Deborah B. Doroshow, William J. Edenfield, ...